DarioHealth Q4 revenue beats estimates, net loss narrows on lower expenses

DarioHealth

19/03/2026 10:38

((This story was generated using AI and automation, please see
disclaimer https://bit.ly/rtrsnai))
    
    Overview
  
    * Digital health platform's Q4 revenue rose sequentially and beat analyst expectations
    * Q4 net loss and operating loss both narrowed and beat analyst expectations
    * Company says full-year revenue decline due to loss of single legacy client, not demand

    
    Outlook
  
    * Company expects contracted ARR of $12.9 mln to contribute revenue in 2026 and 2027
    * DarioHealth expects non-GAAP operating loss to decrease by 30% in 2026
    * Company anticipates continued expansion of MSK product in international markets

    
    Result Drivers
  
    * NEW ARR CONTRACTS - Sequential Q4 revenue growth driven by acceleration in new annual recurring revenue contracts from large employers and health plans
    * OPERATING EFFICIENCIES - Lower operating expenses in Q4 attributed to post-merger integration activities and increased operational efficiency
    * MSK PRODUCT DEMAND - Increased demand for musculoskeletal product in B2C market, with 36% growth in Q4

    
Company press release:  ID:nPn9JHH1Xa 
    
    Key Details
  
                               
                               
 Metric    Beat/Mis  Actual    Consensu
           s                   s
                               Estimate
                               
                               
 Q4        Beat      $5.20     $5.05
 Revenue             mln       mln (4
                               Analysts
                               )
 Q4 Net    Beat      -$9 mln   -$14.93
 Income                        mln (3
                               Analysts
                               )
 Q4        Beat      -$8.60    -$8.89
 Operatin            mln       mln (4
 g Income                      Analysts
                               )
 Q4 Gross            $2.80      
 Profit              mln       
 Q4                  $11.40     
 Operatin            mln       
 g                             
 Expenses                      
    
    Analyst Coverage
  
    * The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
    * The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
    * Wall Street's median 12-month price target for DarioHealth Corp is $20.00, about 124% above its March 18 closing price of $8.93

    
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)